AbbVie still can’t escape Boehringer’s claim that its Humira patent-thicket was wrongful.

The Court in AbbVie’s patent fight over Humira with Boehringer Ingelheim said that it “seems clear enough” that AbbVie had a patenting program designed to mitigate biosimilar entry for Humira®. Though AbbVie clearly danced around ways to avoid producing much of its behind-the-scenes strategizing for building a patent estate sizeable enough to practically coerce settlements, the Court has ordered AbbVie to pull up its skirt.

Markman AdvisorsFebruary 13, 2019AbbVie, ABBV, Boehringer-Ingelheim, Humira, adalimumab, biosimilar, BLA, Delaware, unclean hands, patent thicket, thicket, Zachary Silbersher, Silbersher

Can Merck resurrect its $200M Sovaldi patent judgment against Gilead at the Supreme Court?

Merck ($MRK) lost a $200M patent judgment against Gilead ($GILD) after the Court found that Merck engaged in business and litigation misconduct. Merck is now appealing to the Supreme Court, asking to resurrect that judgment. Will it prevail?

Markman AdvisorsSeptember 28, 2018Merck, $MRK, Gilead, $GILD, Sovaldi, patent, Supreme Court, unclean hands, inequitable conduct, Zachary, Zachary Silbersher, SilbersherComment

Blog

home | team | valuation | consulting | monetization | news | blog